Loading clinical trials...
Loading clinical trials...
PD-L1 and PD-L2 Peptide Vaccination as Consolidation for Relapsed Follicular Lymphoma
Conditions
Interventions
PD-L2 peptide
PD-L2 and PD-L1 peptide
Locations
1
Denmark
Herlev Hospital
Herlev, RegionH, Denmark
Start Date
December 12, 2017
Primary Completion Date
February 12, 2020
Completion Date
February 12, 2020
Last Updated
February 24, 2021
NCT06337318
NCT05006716
NCT06026319
NCT07128641
NCT06510361
NCT01804686
Lead Sponsor
Lars Møller Pedersen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions